Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
80.7 USD | -8.20% | -6.14% | +12.99% |
May. 13 | Ligand Pharmaceuticals Insider Sold Shares Worth $830,449, According to a Recent SEC Filing | MT |
May. 08 | Sector Update: Health Care Stocks Softer Late Afternoon | MT |
Financials (USD)
Sales 2024 * | 138M | Sales 2025 * | 157M | Capitalization | 1.45B |
---|---|---|---|---|---|
Net income 2024 * | 92M | Net income 2025 * | 50M | EV / Sales 2024 * | 10.5 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 9.22 x |
P/E ratio 2024 * |
16.2
x | P/E ratio 2025 * |
25.1
x | Employees | 58 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 97.7% |
Latest transcript on Ligand Pharmaceuticals Incorporated
1 day | -8.20% | ||
1 week | -6.14% | ||
Current month | -5.11% | ||
1 month | +9.20% | ||
3 months | +5.79% | ||
6 months | +34.79% | ||
Current year | +12.99% |
Managers | Title | Age | Since |
---|---|---|---|
Todd Davis
CEO | Chief Executive Officer | 63 | 07-02-28 |
Octavio Espinoza
DFI | Director of Finance/CFO | 53 | 22-10-31 |
President | 49 | 15-08-05 |
Members of the board | Title | Age | Since |
---|---|---|---|
John Kozarich
CHM | Chairman | 74 | 03-02-28 |
John LaMattina
BRD | Director/Board Member | 74 | 11-01-31 |
Stephen Sabba
BRD | Director/Board Member | 64 | 08-08-03 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.24% | 25 M€ | -4.18% | - | |
0.14% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-06-04 | 80.83 | -8.05% | 203,347 |
24-06-03 | 87.91 | +3.36% | 128,569 |
24-05-31 | 85.05 | +1.30% | 122,260 |
24-05-30 | 83.96 | -1.17% | 152,442 |
24-05-29 | 84.95 | -1.20% | 107,499 |
Delayed Quote Nasdaq, June 04, 2024 at 03:59 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+12.99% | 1.58B | |
+42.83% | 748B | |
+34.11% | 598B | |
-5.70% | 356B | |
+18.06% | 325B | |
+4.63% | 283B | |
+17.02% | 245B | |
+9.26% | 211B | |
-4.21% | 209B | |
+2.43% | 166B |
- Stock Market
- Equities
- LGND Stock